Vir Biotechnology's Tobevibart, Elebsiran Combo Gets FDA Fast Track Status for Chronic Hepatitis Delta
By Chris Wack
Vir Biotechnology said the U.S. Food and Drug Administration has cleared its investigational new drug application and granted Fast Track designation for the combination of tobevibart and elebsiran to treat chronic hepatitis delta infection.
The company said tobevibart and elebsiran are currently being evaluated in its Phase 2 hepatitis delta clinical trial. Complete 24-week treatment data is on track to be reported in the fourth quarter.
The FDA's Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
In June, Vir reported preliminary Phase 2 trial data which suggested treatment with tobevibart alone or in combination with elebsiran was generally well tolerated, and participants achieved high rates of virologic response at weeks 12 and 24, durable virologic response through 48 weeks, and high rates of ALT normalization.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 26, 2024 08:51 ET (12:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued